Post by
M101 on Feb 27, 2023 4:42pm
"His exit could cause “reverberations” through the industry"
reverberations? we can only hope
https://www.biopharmadive.com/news/billy-dunn-fda-depart-agency-neuroscience-alzheimers/643627/
Comment by
BottomBroker on Feb 28, 2023 9:05am
Sounds like he had his favorites. A little more impartiality could be a benefit. Maybe. Probably not.
Comment by
M101 on Feb 28, 2023 12:38pm
It's just a little reality window into what any smaller pharma is up against. And why we pay all the suits to play the game. Just another hurdle built into the system to protect big pharma from competition, and not one which is easy to quantify much less mitigate.
Comment by
BottomBroker on Mar 01, 2023 5:55pm
Speaking of which, I thought we were paying a new suit to proposition institutional buyers. So far it seems they don't like what he/she's selling.